Abstract

Steroid hormones modulate adrenergic response and receptors in several tissues. Estrogen treatment results in increased uterine a-adrenergic contraction and also increased a-adrenergic receptors, as quantitated by the binding of the radioligand [3H]dihydroergocryptine (DHE). We asked whether the change in a-adrenergic receptors after estrogen treatment was unique to the uterus or was present in platelets, another tissue known to be affected by estrogen. We used DHE in binding studies of rabbit platelet particulates and found that DHE binding was consistent with interactions expected at an a-adrenergic receptor; binding was high affinity (Kd = 2 nM), low capacity (190–360 fmol/mg protein), and competed for stereoselectively by adrenergic agents with a typical α-adrenergic rank order of potency. Therefore, we used DHE to quantitate a-adrenergic receptors on platelets from oophorectomized or estrogen-treated animals. Estrogen administered by a treatment protocol that has previously been described to decrease...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.